市場調查報告書
商品編碼
1383331
2030 年人類微生物組市場預測:按產品、疾病、類型、應用和地區進行的全球分析Human Microbiome Market Forecasts to 2030 - Global Analysis By Product (Medical Foods, Prebiotics, Probiotics, Symboitics and Other Products), Disease, Type, Application and By Geography |
根據 Stratistics MRC 的數據,2023 年全球人類微生物組市場規模將達到 8 億美元,預計到 2030 年將達到 63 億美元,預測期內年複合成長率為 34.1%。
「人類微生物組市場」一詞定義了專注於人類微生物組的徹底研究、分析和商業性應用的生物技術和醫療領域。它由研究、診斷、治療和個人化醫療等各個領域組成,旨在了解人體與其棲息的微生物之間的共生相互作用。
根據美國癌症協會估計,2022 年美國將報告約 1,918,030 例新癌症病例。此外,根據Globocan 2020統計,新增癌症病例數為274,364例,預計2040年將達到400,564例。
過去幾十年來,微生物組研究取得了重大進展,使我們對微生物組與人類健康和疾病的關係的理解發生了重大變化。此外,由於高通量序列測定方法和強大的生物資訊工具,現在可以對人體內存在的大量微生物群落進行徹底分析和表徵。
主要問題之一是微生物產品和治療方法缺乏透明和統一的法規流程。基於微生物的產品和治療方法缺乏簡單而統一的法律規範可能會限制市場擴張並增加進入障礙。然而,微生物群落的多樣性和人類微生物組的動態性質在評估產品安全性和功效時給法規機構帶來了挑戰。
肥胖、糖尿病、發炎性腸道疾病疾病和自體免疫疾病等慢性疾病在世界各地變得越來越普遍。因此,醫學相關人員和學者正在探索以微生物為基礎的療法,以便更好地了解和管理這些慢性疾病。此外,許多發育技術都涉及恢復慢性病患者的微生物平衡,包括益生菌、糞便微生物移植 (FMT) 和微生物組控制。
微生物組研究領域需要在研發 (R&D) 方面進行大量投資,以充分了解人類微生物組的複雜性並開發基於此的產品和排除項。益生菌和益生元等微生物治療方法的開發、資料分析、臨床試驗和微生物組定序都包含在這些支出中。然而,可用產品和治療方法的多樣性受到高昂的研發成本的阻礙,這可能會阻止小型企業和新興企業進入市場。
全球範圍內的臨床試驗研究因 COVID-19 大流行而受到嚴重干擾。鑑於研究通常包括貧困階級,他們最容易接觸到 COVID-19,這一點尤其重要。同樣,COVID-19 已經並可能對其他公司的營運產生負面影響,包括微生物藥物和診斷設備的臨床前研究和臨床試驗。
預計益生菌產業在預測期內將達到最高水準。益生菌是活的微生物,當以足夠的比例給藥宿主時,可以透過恢復或維持腸道菌叢來改善或維持宿主的整體健康。由於它能夠促進免疫健康、幫助消化和影響一般健康的許多組成部分,因此它變得非常受歡迎。此外,隨著人們越來越重視預防性健康和保健,隨著客戶尋求針對醫療問題的微生物友善治療方法,益生菌產業預計將會成長。
隨著人們越來越認知到人類微生物組在健康和疾病中發揮的重要作用,診斷領域預計將在預測期內呈現最高成長率。由於定序技術和生物資訊學的進步,微生物組診斷可以更深入地了解人體微生物種群,從而實現個體化和精確的治療。此外,微生物組診斷由於其在支持疾病早期檢測、指導個體化治療策略和評估干涉措施成功與否方面的潛力而在醫療保健領域變得越來越普及。
北美地區佔最大佔有率,原因在於其完善的醫療設施網路、大公司加大對開發更先進技術的投資以及加速新藥開發進程。這一領域正變得更加活躍。此外,人類微生物組治療正在引起人們的關注,與文明病變得越來越普遍,人類微生物組的次世代定序和技術進步正在取得進展。所有這些因素都促進了該地區的市場成長。
由於消費者對益生菌、益生元和微生物組相關產品的興趣不斷增加,預計亞太地區將實現盈利成長。這是因為微生物組在消化、營養健康和整體健康方面的重要性正在廣泛認可。此外,亞太地區微生物組科學領域的研發活動正在增加,特別是在中國、日本和韓國等大力投資生物技術和生命科學的國家。
According to Stratistics MRC, the Global Human Microbiome Market is accounted for $0.8 billion in 2023 and is expected to reach $6.3 billion by 2030 growing at a CAGR of 34.1% during the forecast period. The term "Human Microbiomes Market" defines the area of biotechnology and healthcare that focuses on the thorough study, analysis, and commercial applications of the human microbiome, which is the enormous and diverse community of microorganisms that exists both inside and outside the human body. To comprehend the symbiotic interaction between the human body and its resident microorganisms, it comprises a variety of fields, including research, diagnostics, treatments, and customized medicine.
According to the American Cancer Society, 2022 estimates, there are about 1,918,030 new cases of cancer will be reported in the United States in 2022. Additionally, according to the Globocan 2020 statistics, there are 274,364 new cases of cancer and is expected to reach 400,564 new cases by 2040.
An enormous shift has occurred in the comprehension of the human microbiome's involvement in human health and disease as a result of the substantial advancements made in the investigation of it over the past few decades. Additionally, the tremendous community of microorganisms that reside inside the human body has been thoroughly analyzed and characterized because of high-throughput sequencing methods and powerful bioinformatics tools.
The lack of transparent and uniform regulatory processes for microbiome-based products and treatments is one of the main problems. The absence of simple and uniform regulatory frameworks for microbiome-based products and treatments may limit market expansion and increase entry hurdles. However, the variety of microbial communities and the dynamic nature of the human microbiome present difficulties for regulatory authorities when evaluating products' safety and efficacy.
Globally, chronic illnesses such as obesity, diabetes, inflammatory bowel diseases, and autoimmune disorders are becoming more prevalent. As a result, in order to better understand and manage these chronic diseases, medical professionals and academics are exploring microbiome-based therapies. Additionally, the restoration of microbial equilibrium among individuals with chronic illnesses involves a number of developing methods, including probiotics, fecal microbiota transplantation (FMT), and microbiome regulation.
In order to fully comprehend the complexity of the human microbiome as well as develop products and eliminates that are based on it, the field of microbiome research requires significant investments in research and development (R&D). The creation of microbiome therapies like probiotics and prebiotics, as well as data analysis, clinical trials, and microbiome sequencing, are all included in these expenditures. However, the variety of products and treatments available may be hampered by the high cost of R&D, which may prevent smaller businesses and startups from entering the market.
Clinical trial research has been significantly hampered worldwide by the COVID-19 epidemic. Given that studies usually include poor people who are most in danger from COVID-19 exposure, this is very important. Similarly, COVID-19 has had a detrimental effect and might still have one on the operations of other companies, including their preclinical research and clinical testing of microbiome-based drugs and diagnostic instruments.
The segment for probiotics is anticipated to be the largest during the forecast period. Probiotics are living microorganisms that, when administered to a host in sufficient proportions, improve or maintain the host's overall health by restoring or maintaining their intestinal microbiome. Due to their significance in promoting immune health, boosting digestion, and potentially affecting a number of different elements of general wellbeing, they have grown tremendously popular. Furthermore, with an increasing emphasis on preventive health and wellness, the probiotics sector is anticipated to develop as customers look for microbiome-friendly remedies to their medical issues.
Due to the growing awareness of the crucial role played by the human microbiome in health and illness, the diagnostics segment is anticipated to have the highest growth rate throughout the projection period. Microbiome diagnostics can offer a deeper comprehension of the microbial populations within the body due to developments in sequencing technologies and bioinformatics, enabling personalized and precise therapy. Moreover, microbiome diagnostics are also becoming more popular in healthcare due to their potential to support early disease detection, guide individualized treatment strategies, and assess the success of interventions.
North America held the largest share due to an established network of healthcare facilities, greater investment from major firms in developing more advanced technology, accelerating the process of creating new drugs, and a rise in research efforts in this field. Additionally, human microbiome treatments are getting more attention, lifestyle ailments are becoming more prevalent, and next-generation sequencing and the human microbiome are experiencing more technological advancements. These factors are all contributing to the market's growth in the region.
Due to growing consumer interest in probiotics, prebiotics, and microbiome-focused products, the Asia-Pacific area is predicted to experience profitable growth. This is due to digestion, nutritional wellness, and the importance of the microbiome in overall well-being which are becoming more widely recognized. Additionally, the Asia Pacific area has experienced a rise in research and development activities in the field of microbiome science, especially in nations like China, Japan, and South Korea that have made significant investments in biotechnology and the life sciences.
Some of the key players in Human Microbiome market include: Seres Therapeutics, Second Genome Inc., Osel Inc., Exeliom Biosciences SAS, Ginkgo Bioworks, Finch Therapeutics Group Inc., Evelo Biosciences Inc, DuPont, Axial Biotherapeutics, Inc. and Astarte Medical.
In January 2023, Genetic Analysis AS, a research driven diagnostic company that focuses on innovative diagnostic solutions with microbiota analysis, entered into an agreement with Microbiome Research Pvt. Ltd., a India-based microbiome company, for launching a test service portfolio based on the GA-map Dysbiosis Test, and thus, making it the first CE-IVD marked standardized gut microbiome test.